Covid-19

>> How Mursla is helping

Novel early cancer detection platform.

Tracing tumour in the blood.

On-chip platform technology enabling the discovery and quantification of cancer-specific exosome subpopulations in biofluids. 

NPQuantumSense

Platform technology based on nanogap electrodes generating quantum phenomena in biofluids to deliver a novel detection approach for bioactive disease target.

  • Quantum manipulation & sensing in biofluids

  • On-chip format

  • Moore's law scalability

Illustration of nanogap electrodes on chip

Cancer Exosome Targets

Exosomes are the future of early cancer detection.

  • Snapshot of tumour biomarker cargo

  • Contain rare -omics information

  • Influence the tumour microenvironment

Illlustration of exosomes

Latest News

©

2020 Mursla Ltd.

181 Cambridge Science Park, CB4 0GJ, Cambridge, U.K.

  • Twitter - White Circle
  • LinkedIn - White Circle